Science News

Stay updated with the latest scientific news and research. Read press releases covering groundbreaking discoveries, innovations, and developments across various scientific fields. Keep up with the advancements and insights shaping the future of science.

Jun 16, 2026 at 10:16 PM

Tryfacta, Inc. Awarded National Institutes of Health (NIH) Healthcare Staffing Contract

PLEASANTON, Calif.--(BUSINESS WIRE)--Tryfacta, Inc., an artificial intelligence (“AI”)-enabled provider of specialized staffing solutions, today announced that it has been awarded a contract with the National Institutes of Health (NIH) to provide healthcare staffing services in support of NIH operations in Bethesda, Maryland. Performance under the contract is scheduled to begin July 7, 2026. Under this award, Tryfacta will recruit, credential, and deploy qualified clinical and allied health pro...
Jun 16, 2026 at 4:05 PM

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Jun 16, 2026 at 4:05 PM

CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multi-center study, in the Journal of the American Society of Nephrology (JASN). The se...
Jun 16, 2026 at 4:01 PM

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on June 15, 2026, it granted stock options to purchase an aggregate of 103,020 shares of common stock to nine n...
Jun 16, 2026 at 2:53 PM

IQM Deploys Its First U.S. Quantum Computer at Oak Ridge National Laboratory

OAK RIDGE, Tenn. & ESPOO, Finland--(BUSINESS WIRE)--The Department of Energy's Oak Ridge National Laboratory (ORNL) today launched Pathfinder, the first commercially procured quantum computer at ORNL, built and deployed by IQM Quantum Computers. The 20-qubit IQM Radiance system marks IQM's first quantum computer installation in the United States. The deployment comes ahead of IQM's planned listing on the Nasdaq Global Select Market through its business combination with Real Asset Acquisition Co...
Jun 16, 2026 at 12:22 PM

Senopsys Marks 20 Years of Making Medicines Palatable for Patients Worldwide

WOBURN, Mass.--(BUSINESS WIRE)--Senopsys marks 20 years of helping pharma companies develop palatable medicines through sensory science and taste-masking expertise....
Jun 16, 2026 at 12:00 PM

DARPA Selects Quandela for Stage A of the Quantum Benchmarking Initiative

WASHINGTON--(BUSINESS WIRE)--Quandela today announced it has been selected by the U.S. Defense Advanced Research Projects Agency (DARPA) to participate in Stage A of the Quantum Benchmarking Initiative (QBI), a multi-stage program designed to assess whether any quantum computing architecture can achieve utility-scale operation by 2033. Under Stage A, Quandela will present a detailed concept for a utility-scale, fault-tolerant quantum computer, along with technical evidence supporting its near-t...
Jun 16, 2026 at 11:45 AM

Medincell Reports FY 2025-26 Annual Results

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Key Financial Highlights   Total revenues €24.3 million, including €9.3 million of UZEDY® royalties, confirming the evolution of the revenue model Operating result €(20.8) million, reflecting a planned increase in operating expenses to €45.0 million (+17% year-over-year) to support pipeline expansion and long-term value creation Liquidity position €84.8 million2 strengthened by successful fund raising of €48.2 million in March 2026,...
Jun 16, 2026 at 11:00 AM

Nomic and Wellcome Sanger Institute Collaborate to Bring Protein-Level Resolution to the Genetics of Immune Diversity

MONTREAL--(BUSINESS WIRE)--Nomic Bio Inc. announced a research collaboration with the Wellcome Sanger Institute to perform large-scale proteomic profiling of human-derived peripheral blood mononuclear cell (PBMC) supernatant samples generated through Project JAGUAR. By integrating proteomic data with genetic and transcriptomic information from these experiments, the collaboration aims to build one of the most comprehensive functional atlases of human immune variation to date. Project JAGUAR is...
Jun 16, 2026 at 11:00 AM

IFF and ISIPCA Mark 10 Years of Joint Scent Design and Creation Master’s-Level Program

VERSAILLES, France--(BUSINESS WIRE)--IFF — a global leader in flavors, fragrances, food ingredients and health & biosciences — celebrates the 10th anniversary of its industry-leading accredited master's-level program for scent design and creation, developed in partnership with ISIPCA, the world-renowned school for careers in perfume, cosmetics and food flavors. Since its launch in 2016, the IFF ISIPCA program has trained more than 180 professionals from 40 countries, with 130 graduates to d...
Turn Your News Into Headlines
Submit Your Release

Get Story Ideas Delivered to Your Inbox

Sign Up